Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on NeuroPace, Raises Price Target to $30

SVB Leerink analyst Danielle Antalffy maintains NeuroPace (NASDAQ:NPCE) with a Outperform and raises the price target from $25 to $30.

byBenzinga Newsdesk

June 3, 2021

1 minute read

SVB Leerink analyst Danielle Antalffy maintains NeuroPace (NASDAQ:NPCE) with a Outperform and raises the price target from $25 to $30.

Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma

By Vuk Zdinjak

Today, 3:23 AM

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion.

SKYE

News

Biden Says Hopes U.S. Will Not See Same Kind Of Economic Damage From Delta Variant

By Michael Horton

Today, 3:23 AM

-Reuters

SPY

News

Searches For iPod Spike On eBay After Discontinuation

By Chris Katje

Today, 3:23 AM

The discontinuation of a popular music playing device by a tech giant has led to sales of used players seeing increasing attention.

AAPL

Now That FDA Approved TG Therapeutics Multiple Sclerosis Treatment, Analyst Are Boosting Price Targets

By Vandana Singh

Today, 3:23 AM

Wednesday, the FDA approved TG Therapeutics Inc's (NASDAQ: TGTX) Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS).

TGTX

SVB Leerink Maintains Outperform on NeuroPace, Raises Price Target to $30

Related Posts

Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma

Biden Says Hopes U.S. Will Not See Same Kind Of Economic Damage From Delta Variant

Searches For iPod Spike On eBay After Discontinuation

Now That FDA Approved TG Therapeutics Multiple Sclerosis Treatment, Analyst Are Boosting Price Targets